Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Jun;33(6):641–644. doi: 10.1111/j.1365-2125.1992.tb04094.x

The influence of particle size on the bioavailability of inhaled temazepam.

J P Fee 1, P S Collier 1, A P Launchbury 1, R S Clarke 1
PMCID: PMC1381357  PMID: 1389938

Abstract

1. Temazepam was administered by aerosol using a standard protocol to healthy volunteers. Two studies are reported in which different dosage formulations were used: a) 30 mg of the 5 mu diameter particle (n = 6); b) 10 mg of the 2 mu diameter particle (n = 6). 2. An open crossover design was followed in each study. On one occasion in both studies subjects used a gargling procedure to remove drug which had been deposited in the mouth and oropharynx. 3. Serial venous blood samples were drawn for a period of 24 h. The mean total AUC of the 5 mu preparation was significantly reduced by gargling (3153 ng ml-1 h to 1066 ng ml-1 h) (F = 0.32). Gargling also had a significant effect on the mean AUC(0-1 h). 4. In contrast gargling had no significant effect on the mean AUC associated with the smaller diameter particle preparation (630 ng ml-1 h) vs 397 ng ml-1 h (F = 0.74). 5. These findings also indicate that temazepam deposition in the pulmonary tree is enhanced by the use of a 2 mu rather than a 5 mu diameter particle. However, the plasma drug concentrations achieved are unlikely to produce a sufficiently marked sedative effect for endoscopic investigations such as gastroscopy.

Full text

PDF
641

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Elliott P., Dundee J. W., Elwood R. J., Collier P. S. The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. Eur J Anaesthesiol. 1984 Sep;1(3):245–251. [PubMed] [Google Scholar]
  2. Fuccella L. M., Bolcioni G., Tamassia V., Ferrario L., Tognoni G. Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules. Eur J Clin Pharmacol. 1977 Dec 16;12(5):383–386. doi: 10.1007/BF00562455. [DOI] [PubMed] [Google Scholar]
  3. Fuccella L. M., Tosolini G., Moro E., Tamassia V. Study of physiological availability of temazepam in man. Int J Clin Pharmacol. 1972 Nov;6(4):303–309. [PubMed] [Google Scholar]
  4. Hindmarch I. A 1,4-benzodiazepine, temazepam (K 3917), its effect on some psychological parameters of sleep and behaviour. Arzneimittelforschung. 1975 Nov;25(11):1836–1839. [PubMed] [Google Scholar]
  5. Ho P. C., Triggs E. J., Heazlewood V., Bourne D. W. Determination of nitrazepam and temazepam in plasma by high-performance liquid chromatography. Ther Drug Monit. 1983;5(3):303–307. doi: 10.1097/00007691-198309000-00010. [DOI] [PubMed] [Google Scholar]
  6. Ratcliff A., Indalo A. A., Bradshaw E. G., Rye R. M. Premedication with temazepam in minor surgery. The relationship between plasma concentration and clinical effect after a dose of 40 mg. Anaesthesia. 1989 Oct;44(10):812–815. doi: 10.1111/j.1365-2044.1989.tb09097.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES